Omada Health (NASDAQ:OMDA) CAO Craig Gracey Sells 1,042 Shares of Stock

Omada Health, Inc. (NASDAQ:OMDA) CAO Craig Gracey sold 1,042 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $25.00, for a total transaction of $26,050.00. Following the completion of the transaction, the chief accounting officer owned 15,441 shares in the company, valued at approximately $386,025. This represents a 6.32% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Craig Gracey also recently made the following trade(s):

• On Wednesday, July 1st, Craig Gracey sold 637 shares of Omada Health stock. The shares were sold at an average price of $23.00, for a total transaction of $14,651.00.
• On Tuesday, June 30th, Craig Gracey sold 405 shares of Omada Health stock. The stock was sold at an average price of $22.00, for a total transaction of $8,910.00.
• On Monday, June 29th, Craig Gracey sold 2,083 shares of Omada Health stock. The stock was sold at an average price of $21.00, for a total transaction of $43,743.00.
• On Friday, June 26th, Craig Gracey sold 2,084 shares of Omada Health stock. The shares were sold at an average price of $20.00, for a total value of $41,680.00.
• On Wednesday, June 24th, Craig Gracey sold 2,083 shares of Omada Health stock. The shares were sold at an average price of $19.01, for a total value of $39,597.83.
• On Monday, June 22nd, Craig Gracey sold 2,083 shares of Omada Health stock. The stock was sold at an average price of $18.00, for a total value of $37,494.00.
• On Friday, June 12th, Craig Gracey sold 6,894 shares of Omada Health stock. The stock was sold at an average price of $17.42, for a total value of $120,093.48.

Omada Health Price Performance

Shares of NASDAQ:OMDA opened at $23.84 on Thursday. Omada Health, Inc. has a 1 year low of $10.28 and a 1 year high of $26.92. The company has a market cap of $1.46 billion, a P/E ratio of 476.80 and a beta of 1.73. The stock’s fifty day moving average price is $20.74 and its 200-day moving average price is $16.38.

Omada Health (NASDAQ:OMDA) last issued its earnings results on Thursday, August 6th. The company reported $0.08 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.10. The business had revenue of $87.83 million during the quarter, compared to analyst estimates of $80.93 million. Omada Health had a return on equity of 2.67% and a net margin of 1.39%. On average, sell-side analysts anticipate that Omada Health, Inc. will post -0.01 earnings per share for the current year.

Institutional Investors Weigh In On Omada Health

Hedge funds have recently modified their holdings of the business. Quarry LP purchased a new stake in shares of Omada Health in the 4th quarter worth $29,000. TD Waterhouse Canada Inc. bought a new position in Omada Health in the 4th quarter worth $32,000. Raymond James Financial Inc. purchased a new position in Omada Health during the second quarter valued at $32,000. Inlight Wealth Management LLC purchased a new position in Omada Health during the fourth quarter valued at $45,000. Finally, Versant Capital Management Inc grew its holdings in Omada Health by 319.3% during the second quarter. Versant Capital Management Inc now owns 2,998 shares of the company’s stock valued at $66,000 after purchasing an additional 2,283 shares during the period.

Key Headlines Impacting Omada Health

Here are the key news stories impacting Omada Health this week:

• Positive Sentiment: Q2 earnings beat expectations. Omada reported earnings of $0.08 per share, compared with the consensus estimate of a $0.02 loss. Revenue reached approximately $87.8 million, exceeding estimates of $80.9 million. The results indicate that growth in the company’s digital chronic-care business is increasingly translating into profitability. Omada Health Q2 earnings analysis
• Positive Sentiment: Analysts raised their price targets. Robert W. Baird increased its target from $15 to $25 while maintaining a neutral rating. Other recent targets include $27 from Citizens JMP and $35 from BTIG, supporting a broader consensus “Moderate Buy” rating with an average target near $25.67.
• Positive Sentiment: Institutional interest has expanded. Perceptive Advisors and BlackRock established new positions during the second quarter, while Millennium Management significantly increased its stake. These investments may provide support by signaling growing institutional confidence in Omada’s outlook.
• Neutral Sentiment: Short interest is effectively nonexistent. Reported short interest was zero shares, offering no meaningful short-covering catalyst but also indicating limited bearish positioning.
• Negative Sentiment: Several senior executives sold shares. CEO Sean Duffy sold 21,570 shares across two transactions, CFO Steven Cook sold 16,842 shares, President Wei-Li Shao sold 8,866 shares, and Chief Accounting Officer Craig Gracey sold 1,042 shares. The sales totaled approximately $1.16 million, mostly near $25 per share. Although the transactions may reflect personal liquidity or compensation planning, concentrated selling by top executives can weigh on investor sentiment.
• Negative Sentiment: Valuation leaves little room for disappointment. Omada’s market capitalization is approximately $1.46 billion and its reported price-to-earnings ratio is above 475. With shares near the top of their 52-week range, investors may be taking profits despite the earnings beat, particularly while analysts such as Baird remain neutral.

Analyst Ratings Changes

A number of brokerages have weighed in on OMDA. Canaccord Genuity Group boosted their target price on shares of Omada Health from $24.00 to $28.00 and gave the company a “buy” rating in a research note on Tuesday, July 21st. The Goldman Sachs Group reiterated a “buy” rating on shares of Omada Health in a research report on Friday, May 8th. Barclays raised their target price on Omada Health from $20.00 to $25.00 and gave the stock an “overweight” rating in a research report on Monday, August 3rd. Robert W. Baird boosted their price target on Omada Health from $15.00 to $25.00 and gave the company a “neutral” rating in a research note on Wednesday. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $30.00 price target on shares of Omada Health in a research report on Monday, June 22nd. Eleven equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $25.75.

Omada Health Company Profile

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.